re: Ann: Termination of Metabolic vend-in pro... I concur jevalent at last commonsense has prevailed at long last, now the company can get on with what is required to bing their technologies to the forefront, as far as AOD9604 goes all they have to do is see how POH go with their transdermal delivery method goes,they really don't have to spend anything on it yet, if it is shown to be successful, then the IP value of AOD9604 would have to increase dramatically one would think, and perhaps other delivery methods investigated then.
Add to My Watchlist
What is My Watchlist?